Our research
To overcome this clinical uncertainty, we wish to develop mechanism-based laboratory markers with predictive power and offer monitoring possibilities during treatment to individualize dose regimens. This represents a classical Precision Medicine approach and more specifically the present scope is (1) to individualize the use of critical antibiotics against life-threatening infections such as sepsis or endocarditis, by introduction of novel pharmacokinetic-pharmacodynamic modelling tools that helps to define optimal dose in the individual case (2) to explore genetic differences in the highly polymorphic metabolism of tamoxifen and capecitabine in breast cancer treatment in order to secure effective treatment without severe adverse drug reactions.
Senior collaborators (professors/associate professors) include Jonatan Lindh, Sara Margolin, Per Hall, Kamila Czene, Jonas Bergh, Volker Lauschke, Magnus Ingelman-Sundberg, Christian Giske, Johan Petersson (Stockholm), Elisabet Nielsen, Mia Wadelius (Uppsala), and Espen Molden (Oslo).